A5075388937- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- Cancer Risks and Factors
- HER2/EGFR in Cancer Research
- Cancer, Lipids, and Metabolism
- Breast Lesions and Carcinomas
- Advanced Breast Cancer Therapies
- Medical Imaging Techniques and Applications
- Metastasis and carcinoma case studies
- Synthesis and biological activity
- Cytokine Signaling Pathways and Interactions
- NF-κB Signaling Pathways
- Science, Research, and Medicine
- Radiopharmaceutical Chemistry and Applications
- Retinoids in leukemia and cellular processes
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Angiogenesis and VEGF in Cancer
- Glutathione Transferases and Polymorphisms
- interferon and immune responses
- Biomedical and Engineering Education
Queen Elizabeth University Hospital
2011-2024
Western Infirmary
2008-2024
Glasgow Life
2023
University of Glasgow
2004-2023
Southern General Hospital
2015-2020
Erasmus MC Cancer Institute
2018
Johannes Gutenberg University Mainz
2018
Cancer Research UK
2018
Ontario Institute for Cancer Research
2018
Dana-Farber Cancer Institute
2015
Purpose We recently reported that the mRNA-based, 21-gene Genomic Health recurrence score (GHI-RS) provided additional prognostic information regarding distant beyond obtained from classical clinicopathologic factors (age, nodal status, tumor size, grade, endocrine treatment) in women with early breast cancer, confirming earlier reports. The aim of this article is to determine how much contained standard immunohistochemical (IHC) markers. Patients and Methods primary cohort comprised 1,125...
To evaluate the relative effectiveness of letrozole compared with tamoxifen for patients invasive ductal or lobular carcinoma.
Several well-established tumour prognostic factors are used to guide the clinical management of patients with breast cancer. Lymphovascular invasion and angiogenesis have also been reported some promise as factors. The aim present study was examine value lymphovascular microvessel density compared that established in invasive ductal In addition hormone receptor status Ki-67 proliferative activity, their relationship survival were examined Full sections tissue microarrays (n = 384 patients)...
Preoperative staging of the axilla is important to allow decisions regarding neoadjuvant treatment and management axilla. Invasive lobular carcinoma metastases are difficult detect because infiltrative pattern nodal spread. In this study sensitivity preoperative axillary between invasive (ILC) ductal (IDC) was compared.All women diagnosed with pure ILC or IDC in West Scotland 2012-2014 were identified from a database maintained prospectively within Managed Clinical Network. Pretreatment...
Abstract Purpose: Patients with early-stage hormone receptor–positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) and late (5–10 distant (DR) in N0 N1 patients. Here, BCI performance was evaluated HR+ postmenopausal women from the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Experimental Design: 3,544 patients were included analysis (N = 1,519 N0,...
Abstract Background: Invasive lobular carcinoma (ILC) is mostly hormone receptor-positive (ER+) and associated with higher risk of late relapse (> 5 years after diagnosis) when compared to invasive ductal (IDC). In this analysis we investigate the magnitude benefit endocrine treatment (tamoxifen [tam] or letrozole [let]) patterns over time in patients ILC (classical subtype) IDC enrolled monotherapy arms BIG 1-98 study (12-year update). Material methods: was a randomized, phase III...
Abstract Background: There are currently no commercially available tests to identify early stage breast cancer patients treated with conserving surgery (BCS) and systemic therapy at low risk of locoregional recurrence (LRR) for whom postoperative radiotherapy (RT) may be safely omitted. Profile the Omission Local Adjuvant Radiotherapy (POLAR) is a 16-gene molecular signature developed invasive who candidates RT omission after BCS. In this work, we seek validate POLAR in meta-analysis three...
509 Background: Individual risk assessment of distant recurrence (DR) is particularly relevant for early-stage HR+ breast cancer patients, as they face a prolonged even after adjuvant endocrine therapy. Previously, we have shown that the Breast Cancer Index (BCI) and BCIN+ groups are significantly prognostic overall (0-10y) late (5-10y) in N0 N1 respectively, enrolled Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Here, performance BCI continuous score was evaluated TEAM Methods:...
<p>Supplemental Figure 2. Continuous risk curves of BCI and BCIN+ for late 10-year DR in patients DR-free at 5 years. A: as a function continuous N0 (N=1285); B: N1 (N=1625); C: HER2- (N=1063); D: (N=1394).</p>
<p>Supplemental Figure 1. Continuous risk curves of BCI and BCIN+ for overall 10-year DR in patients who did not receive adjuvant chemotherapy. A: as a function continuous N0 (N=1196); B: N1 (N=1234); C: HER2- (N=978); D: (N=1067).</p>
<div>AbstractPurpose:<p>Patients with early-stage hormone receptor–positive (HR<sup>+</sup>) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) and late (5–10 distant (DR) in N0 N1 patients. Here, BCI performance was evaluated HR<sup>+</sup> postmenopausal women from the Tamoxifen Exemestane Adjuvant Multinational (TEAM)...
<div>AbstractPurpose:<p>Patients with early-stage hormone receptor–positive (HR<sup>+</sup>) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) and late (5–10 distant (DR) in N0 N1 patients. Here, BCI performance was evaluated HR<sup>+</sup> postmenopausal women from the Tamoxifen Exemestane Adjuvant Multinational (TEAM)...
<p>Supplemental Figure 1. Continuous risk curves of BCI and BCIN+ for overall 10-year DR in patients who did not receive adjuvant chemotherapy. A: as a function continuous N0 (N=1196); B: N1 (N=1234); C: HER2- (N=978); D: (N=1067).</p>
<p>Supplemental Figure 2. Continuous risk curves of BCI and BCIN+ for late 10-year DR in patients DR-free at 5 years. A: as a function continuous N0 (N=1285); B: N1 (N=1625); C: HER2- (N=1063); D: (N=1394).</p>
Abstract Although therapies exist for breast cancer and mortality rates have fallen, resistance to current remains a major problem. The NF-κB pathways regulate the transcription of wide range genes involved in immune response, inflammation, proliferation apoptosis. Many these processes are hallmarks has been hypothesised be link between inflammation tumourigenesis. aim study was investigate role both pathogenesis recurrence cancer. Immunohistochemistry employed assess key components...
Abstract Background: Adjuvant whole breast radiotherapy (RT) is provided to almost all women with early-stage invasive cancer after conserving surgery and appropriate systemic therapy. While there increasing interest personalize the use of RT based on molecular profiling, date, no signature available reliably assess benefit surgical resection. Here we ability a 16-gene named Profile for Omission Local Radiotherapy (POLAR) identify who may be suitable candidates omission in patients Scottish...
Abstract Background: Women with HR+ breast cancer experience a persistent risk of distant recurrence (DR) even after completion 5 years adjuvant endocrine therapy, more than 50% DR occurring (late DR). The prognostic genomic signatures currently being used in the clinic were not developed or optimized specifically for late DR. We have previously shown that Breast Cancer Index (BCI) and BCIN+ models significantly overall (0-10y) (5-10y) N0 N1 patients Tamoxifen Exemestane Adjuvant...